For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Based on data from its AReSVi-006 trial, the British vaccine maker said Arexvy, compared to a placebo, led to an overall ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

Vaccine vials have to be able to withstand significant stress The pharmaceutical company worker stood at the top of a stairwell, holding a tiny glass vial in their hand. They held the vial out ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

GSK's Arexvy shows strong immune response in adults aged 18-49 at risk for RSV-related respiratory disease. Over 21 million U.S. adults aged 18-49 may be at risk for RSV due to underlying conditions.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine that was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated £1.2 billion ($1.6 billion ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...